Yi Fengshuang, Shi Xinyu, Pei Xuebin, Wu Xiuzhi
Medical Research Center.
Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Medicine (Baltimore). 2018 Nov;97(45):e13160. doi: 10.1097/MD.0000000000013160.
Tumor necrosis factor-alpha (TNF-α) is involved in cancer pathogenesis, and TNF-α-308G>A, a single-nucleotide polymorphism, is associated with cancer prognosis; however, different studies have reported inconsistent results. This meta-analysis aimed to determine the correlation between TNF-α-308G>A polymorphism and the survival of cancer patients.
PubMed, Web of Science, Embase, Wanfang database, VIP database, and China National Knowledge Infrastructure database were used to obtain articles on association between TNF-α-308G>A polymorphism and cancer survival, published until April 2018. A meta-analysis was carried out using Stata 12.0 software to determine the pooled hazard ratio (HR) and 95% confidence intervals (95% CI). Furthermore, publication bias was assessed, and sensitivity analysis was performed to validate the analysis.
In total, 13 retrospective cohort studies including 2559 cancer patients were reviewed to estimate the association between TNF-α-308G>A polymorphism and overall survival (OS) of cancer patients. The pooled results suggested that within TNF-α-308G>A polymorphism, genotypes GA+AA/GG (HR = 1.39, 95% CI: 0.90-2.14, P < .001, I = 78.1%), GA/GG (HR = 1.06, 95% CI: 0.83-1.36, P = .072, I = 53.5%), and AA/AG+GG (HR = 3.28, 95% CI: 0.92-11.72, P = .001, I = 85.9%) were not associated with the OS of cancer patients. However, interestingly, the HR was greater for patients with the AA genotype than for those with the GG genotype, suggesting an association between TNF-α-308G>A polymorphism and OS among cancer patients (AA/GG, HR = 2.16, 95% CI: 1.36-3.43, P = .281, I = 21.5%).
TNF-α-308G>A polymorphism affects the OS of cancer patients and is a potential therapeutic target for cancer.
肿瘤坏死因子-α（TNF-α）参与癌症发病机制，而单核苷酸多态性TNF-α -308G>A与癌症预后相关；然而，不同研究报告的结果并不一致。本荟萃分析旨在确定TNF-α -308G>A多态性与癌症患者生存率之间的相关性。
使用PubMed、Web of Science、Embase、万方数据库、维普数据库和中国知网数据库获取截至2018年4月发表的关于TNF-α -308G>A多态性与癌症生存率关联的文章。使用Stata 12.0软件进行荟萃分析，以确定合并风险比（HR）和95%置信区间（95%CI）。此外，评估发表偏倚，并进行敏感性分析以验证分析结果。
共纳入13项回顾性队列研究，包括2559例癌症患者，以评估TNF-α -308G>A多态性与癌症患者总生存期（OS）之间的关联。汇总结果表明，在TNF-α -308G>A多态性中，基因型GA+AA/GG（HR = 1.39，95%CI：0.90 - 2.14，P <.001，I = 78.1%）、GA/GG（HR = 1.06，95%CI：0.83 - 1.36，P = 0.072，I = 53.5%）和AA/AG+GG（HR = 3.28，95%CI：0.92 - 11.72，P = 0.001，I = 85.9%）与癌症患者的OS无关。然而，有趣的是，AA基因型患者的HR高于GG基因型患者，提示TNF-α -308G>A多态性与癌症患者的OS之间存在关联（AA/GG，HR = 2.16，95%CI：1.36 - 3.43，P = 0.281，I =
